Ipca Laboratories Ltd
Ipca Laboratories is engaged in the manufacturing and marketing of pharmaceuticals.(Source : 201903 Annual Report Page No: 68)
- Market Cap ₹ 40,437 Cr.
- Current Price ₹ 1,594
- High / Low ₹ 1,709 / 1,052
- Stock P/E 58.0
- Book Value ₹ 266
- Dividend Yield 0.25 %
- ROCE 14.2 %
- ROE 9.81 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
Cons
- Stock is trading at 6.00 times its book value
- The company has delivered a poor sales growth of 11.2% over past five years.
- Company has a low return on equity of 11.5% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of Nifty Total Market BSE 250 LargeMidCap Index Nifty LargeMidcap 250 Nifty 500 Multicap 50:25:25 BSE MidCap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2,778 | 3,235 | 3,088 | 2,804 | 3,102 | 3,193 | 3,606 | 4,338 | 5,114 | 5,405 | 5,775 | 6,124 | 6,394 | |
2,216 | 2,498 | 2,556 | 2,526 | 2,666 | 2,748 | 2,909 | 3,419 | 3,596 | 4,164 | 4,858 | 4,909 | 5,074 | |
Operating Profit | 562 | 737 | 532 | 277 | 436 | 446 | 697 | 918 | 1,518 | 1,241 | 917 | 1,215 | 1,321 |
OPM % | 20% | 23% | 17% | 10% | 14% | 14% | 19% | 21% | 30% | 23% | 16% | 20% | 21% |
17 | 21 | 32 | 26 | 19 | 39 | 54 | 64 | 61 | 53 | 108 | -23 | -29 | |
Interest | 34 | 28 | 29 | 31 | 26 | 27 | 21 | 19 | 11 | 10 | 46 | 123 | 88 |
Depreciation | 84 | 101 | 177 | 161 | 171 | 174 | 172 | 179 | 188 | 210 | 229 | 246 | 249 |
Profit before tax | 461 | 629 | 358 | 111 | 258 | 283 | 557 | 785 | 1,380 | 1,074 | 750 | 822 | 955 |
Tax % | 28% | 24% | 28% | 17% | 27% | 18% | 18% | 17% | 17% | 20% | 33% | 35% | |
331 | 477 | 256 | 93 | 188 | 233 | 455 | 652 | 1,141 | 860 | 506 | 530 | 650 | |
EPS in Rs | 13.13 | 18.91 | 10.15 | 3.67 | 7.46 | 9.24 | 18.00 | 25.82 | 44.97 | 33.91 | 19.93 | 20.91 | 25.62 |
Dividend Payout % | 15% | 13% | 5% | 0% | 7% | 5% | 8% | 10% | 9% | 12% | 20% | 19% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | 11% |
3 Years: | 6% |
TTM: | 7% |
Compounded Profit Growth | |
---|---|
10 Years: | 2% |
5 Years: | 6% |
3 Years: | -19% |
TTM: | 26% |
Stock Price CAGR | |
---|---|
10 Years: | 16% |
5 Years: | 23% |
3 Years: | 16% |
1 Year: | 51% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 15% |
3 Years: | 11% |
Last Year: | 10% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
Reserves | 1,545 | 1,956 | 2,208 | 2,258 | 2,450 | 2,670 | 3,111 | 3,652 | 4,727 | 5,450 | 5,852 | 6,323 | 6,713 |
617 | 595 | 929 | 865 | 716 | 628 | 444 | 474 | 236 | 776 | 1,440 | 1,152 | 869 | |
522 | 641 | 662 | 756 | 777 | 785 | 877 | 1,033 | 1,021 | 1,186 | 1,129 | 1,159 | 1,300 | |
Total Liabilities | 2,709 | 3,217 | 3,824 | 3,905 | 3,968 | 4,108 | 4,458 | 5,185 | 6,010 | 7,438 | 8,447 | 8,659 | 8,908 |
1,075 | 1,306 | 1,753 | 1,977 | 1,946 | 1,855 | 1,740 | 1,841 | 1,869 | 2,153 | 2,479 | 2,524 | 2,539 | |
CWIP | 129 | 165 | 267 | 129 | 95 | 73 | 66 | 84 | 182 | 297 | 123 | 175 | 283 |
Investments | 22 | 29 | 82 | 97 | 212 | 216 | 322 | 649 | 868 | 1,339 | 1,057 | 2,654 | 2,721 |
1,482 | 1,717 | 1,722 | 1,702 | 1,716 | 1,964 | 2,329 | 2,611 | 3,092 | 3,650 | 4,789 | 3,306 | 3,365 | |
Total Assets | 2,709 | 3,217 | 3,824 | 3,905 | 3,968 | 4,108 | 4,458 | 5,185 | 6,010 | 7,438 | 8,447 | 8,659 | 8,908 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
387 | 515 | 455 | 696 | 271 | 324 | 496 | 561 | 1,096 | 832 | 762 | 831 | |
-261 | -362 | -686 | -214 | -146 | -119 | -123 | -499 | -560 | -812 | -710 | -1,355 | |
-81 | -138 | 255 | -414 | -156 | -130 | -223 | -139 | -307 | 426 | 506 | -465 | |
Net Cash Flow | 45 | 14 | 25 | 68 | -31 | 74 | 150 | -76 | 229 | 446 | 559 | -990 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 55 | 51 | 42 | 57 | 59 | 68 | 64 | 71 | 55 | 56 | 59 | 61 |
Inventory Days | 245 | 271 | 293 | 290 | 288 | 286 | 332 | 312 | 350 | 364 | 293 | 309 |
Days Payable | 89 | 109 | 97 | 145 | 128 | 136 | 146 | 133 | 121 | 101 | 80 | 78 |
Cash Conversion Cycle | 211 | 213 | 238 | 203 | 219 | 218 | 250 | 250 | 284 | 319 | 272 | 293 |
Working Capital Days | 113 | 98 | 107 | 86 | 95 | 109 | 113 | 117 | 123 | 130 | 123 | 123 |
ROCE % | 24% | 27% | 13% | 4% | 9% | 9% | 17% | 20% | 30% | 19% | 11% | 14% |
Documents
Announcements
-
Closure of Trading Window
7h - Closure of trading window for insiders until financial results.
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 23 Dec
-
Voluntary Closure Of The Company''s Wholly Owned Subsidiary Ipca Pharmaceuticals Ltd SA De CV, Mexico
4 Dec - Voluntary closure of Ipca Pharmaceuticals Ltd SA de CV, Mexico.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 22 Nov
-
Revision In Record Date For Entitlement Of Interim Dividend
18 Nov - Revision of record date for interim dividend.
Annual reports
-
Financial Year 2023
from web
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
Concalls
-
Nov 2024TranscriptPPT
-
Aug 2024TranscriptPPT
-
Jun 2024TranscriptPPT
-
Feb 2024TranscriptPPT
-
Nov 2023TranscriptPPT
-
Aug 2023TranscriptPPT
-
Apr 2023TranscriptPPT
-
Feb 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
Aug 2022TranscriptPPT
-
May 2022TranscriptPPT
-
Feb 2022TranscriptPPT
-
Nov 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Mar 2021TranscriptPPT
-
Nov 2020TranscriptPPT
-
Aug 2020TranscriptPPT
-
Jun 2020TranscriptPPT
-
Feb 2020TranscriptPPT
-
Nov 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Nov 2018TranscriptPPT
Integrated nature of operations
Ipca Laboratories is a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. [1]
IPCA is among India’s top 20 pharmaceutical companies. [2]
Business segments FY22:
API Business (25%) [3]
Ipca produces over 80 APIs, nearly 79% of the APIs and Intermediates business is from exports making them one of India’s top exporters of APIs, serving over 100 countries around the globe. The core strategic focus has been on backward integration, resulting in superior supply chain reliability and cost competitiveness [4] [1] [5]